Advertisement

Topics

Bristol-Myers Squibb makes $12 million investment in Compugen, sets up research partnership

10:30 EDT 11 Oct 2018 | Proactive Investors

New trials will evaluate the safety and tolerability of Compugen’s COM701 in combination with Bristol-Myers' immune checkpoint inhibitor Opdivo in patients with advanced cancerous tumors

Original Article: Bristol-Myers Squibb makes $12 million investment in Compugen, sets up research partnership

NEXT ARTICLE

More From BioPortfolio on "Bristol-Myers Squibb makes $12 million investment in Compugen, sets up research partnership"

Advertisement
Quick Search
Advertisement
Advertisement